Apple's Potential Formula 1 Streaming Rights Purchase
Apple is considering spending $2 billion per year to acquire exclusive Formula 1 streaming rights. This would significantly expand Apple TV+'s live sports offerings.
Key Facts & Points
- Apple may offer $2 billion per year for F1 streaming rights, double current TV rights fees.
- Deal would start with 25% of rights, expanding to 100% over 5 years.
- Apple would pay fixed fee per year rather than increasing price as percentage grows.
- Apple already produces some F1 content for Apple TV+.
- Tim Cook waved checkered flag at 2022 US Grand Prix.
Plummeting Solar Panel Prices Threaten Fossil Fuels
The cost of solar power has dropped 87% in the last decade, reaching a tipping point that makes it cheaper than fossil fuels. This could accelerate the transition to renewable energy and meeting climate targets.
Key Facts & Points
- Solar panel prices have fallen 87% since 2013.
- Battery prices also fell below $100/kWh in August 2022.
- Lower costs make solar power cheaper than fossil fuels.
- This can accelerate the switch to renewable energy.
Vivaldi Browser Brings Desktop Experience to iOS
Vivaldi browser is now available for iOS, bringing desktop-like features such as tab management, notes, and tracker blocking. It aims to provide an alternative to Safari on iPhones and iPads.
Key Facts & Points
- Vivaldi has Speed Dials to organize favorite sites and desktop-style tab bar for easy tab switching.
- Tab Switcher lets you find open, private, recently closed or synced tabs.
- Built-in notes and end-to-end encrypted sync across devices.
- Tracker and ad blocking gives control over how sites display.
New Tooth Regrowth Drug Enters First Human Trial
A new drug developed by a Japanese pharmaceutical company to regrow lost teeth has entered its first clinical human trial. The drug works by inhibiting a gene that typically prevents tooth growth.
Key Facts & Points
- The drug was developed by Toregem Biopharma in Japan.
- It stops proteins that suppress tooth growth by inhibiting the USAG-1 gene.
- First human trials begin in July 2024. The drug could be on the market by 2030.
